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Objective: To observe the effectiveness and safety of a therapy combining disease with syndrome on rheumatoid 
arthritis.   
Methods: Eighty patients with rheumatoid arthritis belonging to syndrome of damp-heat obstruction were randomly 
divided into a treatment group and a control group according to stratified blocked randomization method.Forty 
cases in the control group orally took Loxoprofen Sodium Tablet and Leifumite Tablet and the other 40 cases in the 
treatment group orally took a Chinese medicine for 12 weeks as a course of treatment. ACR therapeutic effect was 
used as the standard for evaluating the total therapeutic effect.  
Results: After 12 weeks of treatment, there was a statistical difference (P<0.01) in the improvement of VAS score, 
morning stiffness time, number of swelling joints, index of swelling joints, number of joints with tenderness, index 
of joints with tenderness, average grip strength of both hands, DSA28 score, HAQ, patient’s assessment, physician’s 
assessment, ESR, CRP and RF in both groups. The improvement of morning stiffness time, number of swelling 
joints, index of swelling joints, grip strength, HAQ and patient’s assessment in the treatment group was much better 
than that in the control groups with statistical difference (P<0.05). ACR20, ACR50 and ACR70 was 27.5% (11/40), 
37.5% (15/40) and 22.5% (9/40) respectively in the treatment group and 40% (16/40), 27.5% (11/42) and 10.0% 
(4/40) respectively in the control group with statistical difference (P<0.05) in the superiority of the treatment group 
over the control group. The incidence of adverse reaction in the control group was higher than that in the treatment 
group (P<0.05).   
Conclusion: Definite therapeutic effect and high safety can be achieved in using the therapy combining disease 
with syndrome to treat rheumatoid arthritis belonging to syndrome of damp-heat obstruction.  
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The main pathological changes in rheumatoid arthritis 
(RA) are manifested in hyperplasia of synovial tissue in 
joints, infiltration of a large number of inflammatory 
cells, progressive destruction of cartilage and vasculitis 
outside joints. The whole course of disease is com- 
prehensively manifested in the 3 pathological processes 
of hyperplasia, inflammation and autoimmune of 
synovial tissue.1 Non-steroidal anti-inflammatory drugs 
can relieve symptoms of joints and alleviate sufferings of 
patients, and illness-condition-improving drugs can delay 
the development of illness condition.2 TCM holds that 
RA belongs to the category of Bi (arthralgia) syndrome, 
which should be mainly treated according to symptoms 
and signs. Pathogeneses and prognoses for various 
diseases of Bi syndrome differ enormously. If the 
treatment is not focused on symptoms and signs, the 
therapeutic effects on RA will be greatly different.  
Pharmacological researches into Chinese drugs have 
shown that many Chinese drugs have the effects of 
eliminating inflammation, stopping pain and inhibiting 
immune. Under the guidance of TCM therapy on 
syndrome differentiation, to correctly select recipes of 
Chinese drugs with the effects of eliminating 
inflammation and inhibiting immune to treat RA (namely, 
to use therapy combining disease with syndrome to treat 
RA) will surely be able to greatly enhance the 
therapeutic effect of TCM on RA.3 In order to verify the 
effectiveness of therapy combining disease with 
syndrome, the authors have carried out a random contrast 
research into RA patients with the most commonly seen 
syndrome of damp-heat obstruction. The result of the 
research is reported as follows.1 
METHODS 
General Data 
Eighty RA patients with the syndrome of damp-heat 
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obstruction at the Third Hospital of Beijing University 
(28 cases), Beijing Military General Hospital (28 cases) 
and Wangjing Hospital of China Academy of Chinese 
Medical Sciences (24 cases) from June 2008 to 
December 2009 were randomly divided into a treatment 
group and a control group according to stratified blocked 
randomization method. The study was carried out with 
the approval from the Ethics Committee of The Third 
Hospital of Beijing University. Informed consent was 
obtained from all the study subjects. 
Method of Administration 
Patients in the control group orally took Loxoprofen 
Sodium Tablet 60 mg, 3 times a day, and Methotrexate 
10–15 mg, once a week. Patients in the treatment group 
orally took a Chinese medicinal decoction of the therapy 
combining disease with syndrome on the basis of the 
above-mentioned treatment. The recipe consisted of Lao 
Guan Cao (Herba Erodii seu Geranii) 15 g, Chuan Shan 
Jia (Squama Manitis) 15 g, Xi Xian Cao (Herba 
Siegesbeckiae) 15 g, Tu Fu Ling (Rhizoma Smilacis 
Glabrae) 15 g, Hu Zhang (Rhizoma Polygoni Cuspidati) 
15 g, Sheng Di Yu (Radix Sanguisorbae) 15 g, Xu Chang 
Qing (Radix Cynanchi Paniculati) 10 g and Ma Huang 
(Herba Ephedrae) 5 g. The decoction was orally taken 
one dose a day in two times. A course of treatment lasted 
12 weeks in both groups. 
Indexes for Observation 
Clinical index: Clinical indexes under observation before 
and after treatment are number of swelling joints and 
index of swelling joints (28 joints are considered. 
Swelling classification is marked with the score of 0, 1 
and 2, which is multiplied by the number of swelling 
joints), number of joints with tenderness and index of 
joints with tenderness (tenderness classification is 
marked with the score of 0, 1, 2 and 3, which is 
multiplied by the number of joints with tenderness), 
average grip strength of both hands, morning stiffness, 
VSA score, DAS28 score, HAQ (health assessment 
questionnaire), patient’s assessment and physician 
assessment. 
Laboratory index: Laboratory index includes blood 
routine, urine routine, hepatic function (ALT and AST), 
renal function (Cr and BUN), erythrocyte sedimentation 
rate (ESR), C reaction protein (CRP) and rheumatoid 
factor (RF).  
Standard of Diagnosis 
Standard of diagnosis in Western medicine: 
All the patients under observation conformed to the 
standard of classifying RA stipulated by US Rheumatism 
Association in 1987:4 1) Morning stiffness lasts at least 1 
hour (>6 weeks). 2) Swelling occurs in 3 or more joints 
(>6 weeks). 3) Swelling occurs in joints of the wrist, 
palm and near-end fingers (>6 weeks). 4) Swelling 
occurs in symmetric joints (>6 weeks). 5) Nodes occur 
under the skin. 6) Changes can be seen in roentgenogram 
of hands (at least showing osteoporosis and narrowed 
joint gap. 7) Rheumatoid factors are positive (titer >1:32).  
Patients conforming to 4 or more of the above-mentioned 
7 items can be diagnosed as suffering from rheumatoid 
arthritis. 
Standard of diagnosing the syndrome of damp-heat 
obstruction in TCM5: Major symptoms are swelling pain 
and hot sensation in joints, fever, limited flexion and 
extension of joints and morning stiffness. Minor 
symptoms are thirst, perspiration, deep yellow urine, dry 
stool, red tongue with yellow, thick and greasy fur, and 
slippery and rapid or wiry and rapid pulse. 
Standard of Inclusion 
Patients are 18–70 years old, conform to 1–3 grade in 
roentgenogram grading and sign an agreement of 
knowing condition of clinical research. 
Standard of Exclusion 
1) Patients have severe diseases of the liver, kidney, 
cardiac and cerebral blood vessels, respiratory system, 
blood and endocrine. 2) Patients have active gas- 
trointestinal diseases. 3) Women are in pregnancy or in 
lactation period. 4) Patients are sensitive to any drug in 
the recipe. 
Standard of Judging Therapeutic Effect 
The therapeutic effect is judged with ACR20, ACR50 
and ACR70 stipulated by US Rheumatoid Association.6 
ACR20 is defined as follows. Swelling and tenderness in 
28 joints are alleviated by 20% and there is 20% 
improvement in at least 3 of the following 5 items: 1) 
rest pain, 2) daily life ability, 3) physician’s assessment, 
4) patient’s assessment and 5) reaction substances (ESR 
or CRP) at acute stage. ACR50 and ACR70 are defined 
as improvement by 50% and 70% respectively according 
to the same standard. 
Statistical Method 
SAS8.0 statistical software is used for processing data, 
which are expressed with x f s. T test is used to 
compare measurement data conforming to normal 
distribution between the two groups. Wilcoxon test is 
used to compare measurement data not conforming to 
normal distribution. Chi-square test is used to compare 
enumeration data. Ridit analysis is used for classified 
data. Obvious bound is determined as 0.05. 
RESULTS 
Comparison of Baseline Data between the 2 Groups 
Among the 40 cases in the treatment group were 11 
males and 29 females aged 49.0±12.6 with their illness 
course of 32.5±28.0 months. Among the other 40 cases 
in the control group were 12 males and 28 females aged 
52.6±10.1 with their illness course of 38.0±24.3 months. 
There was no statistical difference in sex, age, illness 
course, illness condition and other baseline data between 
the two groups (P>0.05, Table 1).  
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Comparison of Clinical and Laboratory Indexes 
before and after Treatment in the 2 Groups 
After 12 weeks of treatment, there were statistical 
differences (P<0.01) in the improvement of VAS score, 
morning stiffness time, number of swelling joints, index 
of swelling joints, number of joints with tenderness, 
index of joints with tenderness, grip strength, DAS28 
score, HAQ, patient’s assessment, physician’s ass- 
essment, ESR, CRP and RF in the 2 groups. The 
improvement of VAS score, morning stiffness time, 
number of swelling joints, index of swelling joints, 
number of joints with tenderness, index of joints with 
tenderness, grip strength, DAS28 score, HAQ, patient’s 
assessment and ESR in the treatment group was better 
than that in the control group with statistical difference 
(P<0.05, Table 1). 
Table 1. Comparison of clinical and laboratory indexes before and after treatment in the 2 groups ( xfs) 
Treatment group (40 cases) Control group (40 cases) 
Item    Before treatment After treatment Before treatment After treatment 
T P value 
VAS (10 cm)      6.80±1.60  3.65±1.28Ƹ  6.17±1.18  3.53±1.11Ƹ 2.149 0.036 Ÿ 
Morning stiffness (min) 124.33±83.73  42.33±21.68Ƹ 102.81±78.45  54.69±33.43Ƹ 2.078 0.043Ÿ 
Number of swelling joints 11.83±5.91  3.07±1.11Ƹ 12.09±7.10 17.88±6.11Ƹ 2.037 0.046Ÿ 
Index of swelling joints  29.73±11.78 10.37±3.48Ƹ  31.47±16.13 17.88±6.11Ƹ 2.071 0.043Ÿ 
Mumber of joints with tenderness  17.37±8.43  5.77±1.94Ƹ 16.53±6.23  8.44±2.51Ƹ 2.073 0.043Ÿ 
Index of joints with tenderness  27.77±9.35 15.40±6.33Ƹ 26.94±8.38  8.44±2.51Ƹ 2.091 0.041Ÿ 
Grip strength (mmHg)  71.80±45.02 113.33±39.32Ƹ  86.00±38.96 121.02±38.86Ƹ 2.087 0.041Ÿ 
DAS28 score  6.13±1.53  3.83±1.21Ƹ  5.72±2.02  3.81±1.69Ƹ 2.502 0.015Ÿ 
HAQ  1.87±0.68  0.67±0.66Ƹ  1.78±0.75  0.81±0.74Ƹ 2.870 0.007ƾ 
Patient’s assessment  6.13±1.57  2.87±1.04Ƹ  5.91±1.92  3.19±1.33 Ƹ 2.771 0.007ƾ 
Physician’s assessment  6.90±1.32  2.93±0.83Ƹ  6.69±1.69  3.22±1.07Ƹ 2.497 0.797 
ESR (mm/h)  45.40±24.34 18.53±9.47Ƹ  41.44±23.13  23.66±10.17Ƹ 2.037  0.046Ÿ 
CRP (mg/L)  27.51±30.98  7.83±4.66Ƹ  25.98±31.93 11.09±7.82Ƹ 0.707 0.482 
RF (IU/mL) 129.22±82.99  37.43±17.51Ƹ  118.66±109.53  43.41±23.47 Ƹ 0.807 0.423 
Notes: ƸP<0.01 as compared to the datum before treatment in the same group; ŸP<0.05 as compared to the difference with the datum in the 
control group; *P<0.01 as compared to the difference with the datum in the control group. 
 
Comparison of ACR Therapeutic Effects between the 
2 Groups  
The ACR therapeutic effect in the treatment groups was 
better than that in the control group with statistical 
difference (P<0.05, Table 2). 
Adverse Reaction  
The incidence of adverse reaction in the control groups 
was higher than that in the treatment group with 
statistical difference (P<0.05, Table 3). 
Table 2. Comparison of ACR therapeutic effects between the 2 groups˄Cases (%)˅ 
Group Cases <ACR20 ACR20 ACR50 ACR70 Ȥ2 P value 
Treatment group 40 5 (12.5) 11 (27.5) 15 (37.5) 9 (22.5) 3.8588 0.0358 
Control group 40 9 (22.5) 16 (40.0) 11 (27.5) 4 (10.0) - - 
Table 3. Comparison of incidence of adverse reaction between the 2 groups˄Cases (%)˅ 
Group   Cases Reduction in 
white cells  
(%) 
Damage to 
hepatic 
function (%) 
Gastrointestinal 
reaction 
 (%) 
Others  
(%) 
Total 
(%) 
Ȥ2 P value 
Treatment group 40 1 (3.33) 0 (0.00) 1 (3.33) 0 (0.00) 2 (6.67)   
Control group 40 3 (9.38) 1 (3.13) 3 (9.38) 1 (3.13) 8 (25.00) 3.8472 0.0498 
 
DISCUSSION 
TCM holds that RA belongs to the category of Bi 
syndrome. Since ancient time, treatment according to 
symptoms and signs has been used as TCM therapeutic 
principle. However, RA and common Bi syndrome differ 
in nature not only in pathogenesis but also in prognosis.  
Bi syndrome may be effectively treated with a method to 
eliminate inflammation and stop pain. However, RA 
belonging to a lifelong immune disease should be treated 
with immune inhibition to control the development of 
illness. Therefore, treatment should be focused on 
symptoms and signs in treating RA, that is to say, the 
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treatment according to symptoms and signs should be 
based on pharmacological researches into Chinese drugs 
and on RA-treating concept in Western medicine. In the 
past several decades, great progress has been made in 
pharmacological researches into Chinese drugs, 
providing energetic support for the therapy combining 
disease with syndrome. 
In this research focusing on the most commonly seen RA 
syndrome of damp-heat obstruction, the authors explored 
the effectiveness and safety of the therapy combining 
disease with syndrome on RA. The result of the research 
showed that after 12 weeks of treatment, there was 
statistical significance (P<0.01) in the improvement of 
VAS score, morning stiffness time, number of swelling 
joints, index of swelling joints, number of joints with 
tenderness, index of joints with tenderness, grip strength, 
DAS28 score, HAQ, patient’s assessment, physician’s 
assessment, ESR, CRP and RF in the 2 groups. The 
improvement of VAS score, morning stiffness time, 
number of swelling joints, index of swelling joints, 
number of joints with tenderness, index of joints with 
tenderness, grip strength, DAS28 score, HAQ, patient’s 
assessment and ESR in the treatment group was better 
than that in the control group with statistical difference 
(P<0.05). ACR therapeutic effect in the treatment group 
was also better than that in the control group (P<0.05). 
The incidence of adverse reaction in the control group 
was much higher than that in the treatment group 
(P>0.05), indicating that TCM therapy combining 
disease with syndrome has definite therapeutic effect and 
high safety in the treatment of RA. 
In the recipe, Xi Xian Cao (Herba Siegesbeckiae) can 
inhibit the generation of IL-1 in rats with arthritis, thus 
preventing IL-1 from damaging the cartilage and bone in 
joints of rats, alleviating the process of whole and local 
pathological changes, and having obvious analgesic 
effect.7
 Total tannins of Lao Guan Cao (Herba Erodii seu 
Geranii) has the effects of eliminating inflammation, 
inhibiting immune and stopping pain.8 Saponins of 
Chuan Shan Jia (Squama Manitis) has obvious effect of 
inhibiting the immune function of body fluid and cell.9  
Tu Fu Ling (Rhizoma Smilacis Glabrae) can obviously 
inhibit the swelling in feet of rats with arthritis and 
noticeably reduce the frequency of body-twisting 
reaction of mice, indicating that Tu Fu Ling has obvious 
anti-inflammatory and analgesic effects.10 Hu Zhang 
(Rhizoma Polygoni Cuspidati), Sheng Di Yu (Radix 
Sanguisorbae), Xu Chang Qing (Radix Cynanchi 
Paniculati) and Ma Huang (Herba Ephedrae) have anti- 
inflammatory and analgesic effects to different 
extent.11-14 Xi Xian Cao, pungent and bitter in taste and 
dispersive and dry in nature, acts as a monarch drug to 
remove damp-heat, eliminate rheumatism, relieve 
arthralgia and stop pain. Lao Guan Cao and Chuan Shan 
Jia act as minister drugs to dispel wind, remove 
dampness, relax muscles, clear collaterals and treat heat 
arthralgia. Tu Fu Ling, sweet in taste, can eliminate toxin, 
remove dampness and disperse damp-heat from lower 
jiao. Hu Zhang, better in taste and cold in nature, is good 
at eliminating toxin, repelling dampness, promoting 
blood circulation and removing blood stasis. Sheng Di 
Yu, bitter in taste and slightly cold in nature, can remove 
toxin and clear away heat from blood. Xu Chang Qing 
and Ma Huang, pungent in taste and dispersive in nature, 
can dispel wind and dampness from the body surface and 
restrict the above-mentioned drugs, bitter in taste and 
cold in nature, from damaging yang-qi. Xu Chang Qing, 
Ma Huang, Tu Fu Ling, Hu Zhang and Sheng Di Yu act 
as adjuvant and conductant drugs. All the drugs are used 
together to remove damp-heat and stop arthralgia- pain. 
The recipe is characterized by combination of dif- 
ferentiating disease with differentiating syndrome, 
embodying the wholeness and flexibility of treatment 
according to symptoms and signs, effectively treating 
dysfunction of immune, inflammatory reaction and other 
pathological changes, integrating the characters of 
treating RA in TCM with Western medicine and 
theoretically embodying the therapeutic thought of 
combination of TCM with Western medicine. Therefore, 
the therapy is worth further studying and popularizing. 
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